ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2566

Aβ-Related Angiitis: Comparison with Patients with Amyloid Cerebral Angiopathy without Inflammation

Carlo Salvarani1, Caterina Giannini2, Robert D. Brown Jr.2, Teresa J. H. Christianson2 and Gene G. Hunder3, 1Rheumatology, Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy, 2Mayo Clinic, Rochester, MN, 3Rheumatology, Mayo Clinic, Rochester, MN

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Vasculitis: Clinical Aspects

Session Type: Abstract Submissions (ACR)

Background/Purpose:  Coexistence of sporadic cerebral amyloid angiopathy (CAA) and primary central nervous system vasculitis (PCNSV) has been reported, particularly in patients with granulomatous vasculitis. This condition was termed Aβ–related angiitis (ABRA).  We analyzed the clinical, radiographic, and pathological findings in a series of consecutive patients with pathologically diagnosed CAA.  We describe the clinical characteristics of the patients with ABRA and compare them with the characteristics of patients with CAA without inflammation. Furthermore, we compare the features of patients with ABRA with those of PCNSV. Methods:  We reviewed all patients seen at the Mayo Clinic, Rochester, MN over the 25 year period of 1987 to 2011, who were diagnosed pathologically with CAA. Biopsy specimens were reviewed by one pathologist (CG) without knowledge of clinical information. Patients with changes of Alzheimer’s disease were excluded. Of 74 identified patients, 46 did not show inflammation, 23 had ABRA, and 5 CAA-related inflammation (perivascular only).  We also utilized our updated cohort of 131 consecutive patients with PCNSV seen over a 25 year period of 1983 to 2007 at Mayo Clinic, Rochester, MN.  The diagnosis of PCNSV was based on brain/spinal cord biopsy or cerebral angiography, or both.  14/131 patients had ABRA. 9 additional patients with ABRA were identified between 2008 and 2011. Results:  The 23 patients with ABRA were compared with the 46 cases with CAA without inflammation. The presence of altered cognition (15/23 or 65.2% vs 41/46 or 89.1%. p = 0.017), hemiparesis (3/23 or 13% vs 18/46 or 39.1%, p = 0.026), persistent neurologic deficit or stroke (5/23 or 21.7% vs 25/46 or 54.3%, p = 0.010), and intracranial hemorrhage (2/23 or 8.7% vs 31/46 or 67.4%, p < 0.001) at presentation  were significantly less frequent in patients with ABRA than in the others. More patients with ABRA showed meningeal gadolinium enhancing lesions at MRI (13/23 or 56.5% vs 7/26 or 26.9%, p = 0.035). No differences in the demographics and cerebrospinal fluid (CSF) findings were observed in the two groups.  Survival of the patients with CAA without inflammation was significantly lower compared to that of those with ABRA.  The 23 patients with ABRA were compared to the other 117 patients with PCNSV (excluding the 14 patients with ABRA). The median age of patients with ABRA was significantly higher at diagnosis (67 years vs 47 years, p < 0.001). In ABRA patients, hemiparesis occurred less frequently at presentation (3/23 or 13% vs 51/117 or 43.6%, p =0.006), while gadolinium enhanced meningeal lesions occurred more frequently (13/23 or 56.5% vs 12/104 or 11.5%, p < 0.001). CSF abnormalities (a protein level > 700 mg/L) were observed more frequently in patients with ABRA (15/20 or 75% vs 40/90 or 47.1%, p = 0.024). The median protein CSF levels were higher in patients with ABRA (995 mg/L vs 660 mg/L, p = 0.009). No differences in the survival were observed between these 2 groups. Conclusion:  ABRA  appears to represent a condition clinically distinct from CAA and PCNSV. However, the vasculitis seems to influence the clinical findings to a greater degree than the presence of amyloid deposits in the vessels.


Disclosure:

C. Salvarani,
None;

C. Giannini,
None;

R. D. Brown Jr.,
None;

T. J. H. Christianson,
None;

G. G. Hunder,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a%ce%b2-related-angiitis-comparison-with-patients-with-amyloid-cerebral-angiopathy-without-inflammation/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology